MSCs Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma

Diffuse intrinsic pontine glioma (DIPG) is among the deadliest of pediatric brain tumors. Radiation therapy is the standard of care treatment for DIPG, but offers only transient relief of symptoms for DIPG patients without providing significant survival benefit. Oncolytic virotherapy (OV) is an anticancer treatment that has been investigated for treating various types of brain tumors. Here, we have explored the use of mesenchymal stem cells (MSC) for OV delivery and evaluated treatment efficacy using preclinical models of DIPG. Our results show that DIPG cells and tumors exhibit robust expression of cell surface proteins that are important for OV entry, and that MSCs loaded with OV disseminate within and release OV throughout the tumor in mice bearing DIPG brainstem xenografts. When combining administration of OV-loaded MSCs with radiotherapy, mice bearing brainstem DIPG xenografts experience a significant survival benefit, relative to that conferred by either therapy alone (p<0.0001). Our results support further preclinical investigation of cell-based OV therapy with radiation for potential translation in treating DIPG patients.

[1]  Deliang Guo,et al.  oHSV therapy increases trametinib access to brain tumors and sensitizes them in vivo. , 2019, Neuro-oncology.

[2]  M. Monje,et al.  The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models , 2019, Nature Communications.

[3]  C. James,et al.  Tenascin-C expression contributes to pediatric brainstem glioma tumor phenotype and represents a novel biomarker of disease , 2019, Acta Neuropathologica Communications.

[4]  E. Hulleman,et al.  Preclinical therapeutic targets in diffuse midline glioma. , 2019, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[5]  I. Balyasnikova,et al.  Pharmacologic modulation of nasal epithelium augments neural stem cell targeting of glioblastoma , 2019, Theranostics.

[6]  G. Sukhorukov,et al.  Safe and Effective Delivery of Antitumor Drug Using Mesenchymal Stem Cells Impregnated with Submicron Carriers. , 2019, ACS applied materials & interfaces.

[7]  Xiaoyi Sun,et al.  Mesenchymal stem cells loaded with paclitaxel-poly(lactic-co-glycolic acid) nanoparticles for glioma-targeting therapy , 2018, International journal of nanomedicine.

[8]  V. J. D. da Silva,et al.  Therapy With Mesenchymal Stem Cells in Parkinson Disease: History and Perspectives , 2018, The neurologist.

[9]  J. Panyam,et al.  Nano-Engineered Mesenchymal Stem Cells Increase Therapeutic Efficacy of Anticancer Drug Through True Active Tumor Targeting , 2018, Molecular Cancer Therapeutics.

[10]  E. Bongarzone,et al.  microRNA-219 Reduces Viral Load and Pathologic Changes in Theiler's Virus-Induced Demyelinating Disease. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[11]  Murad Alahdal,et al.  Nano-loaded human umbilical cord mesenchymal stem cells as targeted carriers of doxorubicin for breast cancer therapy , 2018, Artificial cells, nanomedicine, and biotechnology.

[12]  H. Park,et al.  Developing chemotherapy for diffuse pontine intrinsic gliomas (DIPG). , 2017, Critical reviews in oncology/hematology.

[13]  Chae-Ok Yun,et al.  A hydrogel matrix prolongs persistence and promotes specific localization of an oncolytic adenovirus in a tumor by restricting nonspecific shedding and an antiviral immune response. , 2017, Biomaterials.

[14]  Michael E. Lassman,et al.  Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy , 2017, Cell.

[15]  A. Shilatifard,et al.  Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma , 2017, Acta neuropathologica communications.

[16]  V. Takiar,et al.  Radiation and subsequent reirradiation outcomes in the treatment of diffuse intrinsic pontine glioma and a systematic review of the reirradiation literature. , 2017, Practical radiation oncology.

[17]  John D Lambris,et al.  Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies , 2016, Molecular therapy oncolytics.

[18]  Atique U. Ahmed,et al.  Intranasal Oncolytic Virotherapy with CXCR4-Enhanced Stem Cells Extends Survival in Mouse Model of Glioma , 2016, Stem cell reports.

[19]  David T. W. Jones,et al.  Pediatric high-grade glioma: biologically and clinically in need of new thinking , 2016, Neuro-oncology.

[20]  M. Caligiuri,et al.  TGFβ Treatment Enhances Glioblastoma Virotherapy by Inhibiting the Innate Immune Response. , 2015, Cancer research.

[21]  I. Herr,et al.  Engineered adenoviruses combine enhanced oncolysis with improved virus production by mesenchymal stromal carrier cells , 2015, International journal of cancer.

[22]  Hal Blumenfeld,et al.  Neurostimulation to improve level of consciousness in patients with epilepsy. , 2015, Neurosurgical focus.

[23]  K. Ichimura,et al.  Revisiting TP53 Mutations and Immunohistochemistry—A Comparative Study in 157 Diffuse Gliomas , 2015, Brain pathology.

[24]  A. Cohen-Gadol,et al.  Novel delivery methods bypassing the blood-brain and blood-tumor barriers. , 2015, Neurosurgical focus.

[25]  L. Galluzzi,et al.  Molecular mechanisms of cell death: central implication of ATP synthase in mitochondrial permeability transition , 2015, Oncogene.

[26]  R A Moats,et al.  Analysis of glioblastoma tumor coverage by oncolytic virus-loaded neural stem cells using MRI-based tracking and histological reconstruction , 2014, Cancer Gene Therapy.

[27]  Atique U. Ahmed,et al.  Advances in stem cells, induced pluripotent stem cells, and engineered cells: delivery vehicles for anti-glioma therapy , 2014, Expert opinion on drug delivery.

[28]  L. Galluzzi,et al.  Molecular mechanisms of cell death: central implication of ATP synthase in mitochondrial permeability transition , 2014, Oncogene.

[29]  Barbara S. Paugh,et al.  Novel oncogenic PDGFRA mutations in pediatric high-grade gliomas. , 2013, Cancer research.

[30]  Atique U. Ahmed,et al.  A preclinical evaluation of neural stem cell-based cell carrier for targeted antiglioma oncolytic virotherapy. , 2013, Journal of the National Cancer Institute.

[31]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[32]  M. Prados,et al.  Characterization of a diffuse intrinsic pontine glioma cell line: implications for future investigations and treatment , 2012, Journal of Neuro-Oncology.

[33]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[34]  W. Vandertop,et al.  Diffuse intrinsic pontine gliomas: a systematic update on clinical trials and biology. , 2012, Cancer treatment reviews.

[35]  L. Ketonen,et al.  Palliative Reirradiation for Progressive Diffuse Intrinsic Pontine Glioma , 2012, American journal of clinical oncology.

[36]  Li Ding,et al.  Somatic Histone H3 Alterations in Paediatric Diffuse Intrinsic Pontine Gliomas and Non-Brainstem Glioblastomas , 2012, Nature Genetics.

[37]  Atique U. Ahmed,et al.  A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma. , 2011, Molecular pharmaceutics.

[38]  R. Weissert,et al.  Therapeutic efficacy of intranasally delivered mesenchymal stem cells in a rat model of Parkinson disease. , 2011, Rejuvenation research.

[39]  Atique U. Ahmed,et al.  Bone marrow mesenchymal stem cells loaded with an oncolytic adenovirus suppress the anti-adenoviral immune response in the cotton rat model. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[40]  Richard G Grundy,et al.  Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Michael D. Prados,et al.  A human brainstem glioma xenograft model enabled for bioluminescence imaging , 2009, Journal of Neuro-Oncology.

[42]  W. Frey,et al.  Intranasal delivery of cells to the brain. , 2009, European journal of cell biology.

[43]  A. Sonabend,et al.  Biodistribution of an oncolytic adenovirus after intracranial injection in permissive animals: a comparative study of Syrian hamsters and cotton rats , 2009, Cancer Gene Therapy.

[44]  C. Glackin,et al.  Neural Stem Cell Tropism to Glioma: Critical Role of Tumor Hypoxia , 2008, Molecular Cancer Research.

[45]  K. Lamborn,et al.  Neuro-oncology New Therapeutic Approach for Brain Tumors: Intranasal Delivery of Telomerase Inhibitor Grn163 , 2006 .

[46]  J. Mathis,et al.  Mesenchymal Stem Cells Effectively Deliver an Oncolytic Adenovirus to Intracranial Glioma , 2008, Stem cells.

[47]  R. Weissleder,et al.  Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. , 2007, Journal of the National Cancer Institute.

[48]  H. Atkins,et al.  Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[49]  A. Rivera,et al.  Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma. , 2007, Human gene therapy.

[50]  M. Caligiuri,et al.  Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses , 2006, Proceedings of the National Academy of Sciences.

[51]  M. Lamfers,et al.  The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma. , 2006, Journal of neurosurgery.

[52]  N. Takai,et al.  Expression of survivin is associated with malignant potential in epithelial ovarian carcinoma. , 2002, International journal of molecular medicine.

[53]  D. Altieri,et al.  Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[54]  M. Berger,et al.  Pediatric brain stem tumors: radiographic, pathological, and clinical correlations. , 1983, Neurosurgery.

[55]  F. Lang,et al.  Stem Cell Therapy of Gliomas. , 2018, Progress in neurological surgery.

[56]  R. Verhaak,et al.  GlioVis data portal for visualization and analysis of brain tumor expression datasets. , 2017, Neuro-oncology.

[57]  Atique U. Ahmed,et al.  Intranasal delivery of mesenchymal stem cells significantly extends survival of irradiated mice with experimental brain tumors. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[58]  T. MacDonald,et al.  Comparative multidimensional molecular analyses of pediatric diffuse intrinsic pontine glioma reveals distinct molecular subtypes , 2013, Acta Neuropathologica.

[59]  J. Y. Lee,et al.  Human adipose tissue-derived mesenchymal stem cells: characteristics and therapeutic potential as cellular vehicles for prodrug gene therapy against brainstem gliomas. , 2012, European journal of cancer.

[60]  O. Bogler,et al.  Human Bone Marrow – Derived Mesenchymal Stem Cells for Intravascular Delivery of Oncolytic Adenovirus Δ 24-RGD to Human Gliomas , 2022 .